Latest News

In recent months, Arbor Realty Trust has faced weaker net interest income growth, rising loan distress in its roughly US$12.00 billion portfolio, and a dividend cut following a soft first-quarter 2026 earnings report. Together with declining earnings per share, tangible book value per share, and earnings estimates, these developments highlight mounting profitability and credit pressures tied to tougher commercial real estate conditions. Next, we’ll examine how the elevated distress in...

C3.ai, Inc. reported past fourth-quarter revenue of US$51.6 million and a full-year total of US$250.27 million to 30 April 2026, alongside wider net losses and loss per share compared with the previous year. At the same time, C3.ai is extending its multi-year collaboration with Shell to deepen AI-driven reliability and root-cause analysis across Shell’s global operations, underscoring a contrast between customer adoption progress and internal execution challenges. We’ll now examine how...

As Australian shares follow Wall Street into the red, with geopolitical tensions and economic uncertainties casting a shadow over market sentiment, investors are increasingly seeking refuge in more stable sectors like consumer staples. In such volatile times, growth companies with high insider ownership can offer a compelling investment narrative as they often signal strong confidence from those who know the business best.

In the midst of a challenging period for Australian shares, with market sentiment swayed by geopolitical tensions and economic uncertainties, investors are increasingly on the lookout for opportunities in undervalued stocks. Identifying stocks that may be trading below their estimated value can offer potential upside, especially when broader market volatility prompts a shift towards more defensive investment strategies.

Australian shares have been under pressure, mirroring Wall Street's downturn amid geopolitical tensions and economic uncertainties. Despite the market's current volatility, investors can still find opportunities by focusing on companies with strong financials and growth potential. Penny stocks, although an older term, continue to represent smaller or newer companies that may offer significant value; we'll explore three such stocks on the ASX that stand out for their financial strength and...

Earlier this week, Lazard reported preliminary May 2026 assets under management of about US$284.8 billion, with US$11.6 billion of market appreciation offset by US$1.4 billion in client withdrawals and US$0.7 billion of currency depreciation. At the same time, recent insider share sales without any reported insider buying have raised fresh questions about how management views near-term business conditions. We’ll now examine how Lazard’s recent net outflows and currency headwinds may...

Li Auto Inc. reported past May 2026 deliveries of 33,350 vehicles, taking cumulative deliveries to about 1.70 billion units by May 31, alongside first-quarter 2026 revenue of CNY 22,982.91 million and a net loss of CNY 2,289.53 million. Alongside weaker recent deliveries and guidance flagging year-over-year declines in second-quarter volumes and revenue, Li Auto is updating its product lineup and bylaws while preparing for a European launch and a June technology showcase. We’ll now examine...

Why Endeavour Mining Stock Is on Investors’ Radar Endeavour Mining (TSX:EDV) has been drawing attention after a period where the stock fell 5.6% over the past day and 27.7% over the past month, prompting fresh interest in its fundamentals. See our latest analysis for Endeavour Mining. Despite the recent share price pullback, including a 30 day share price return that is down 27.7% and a 90 day share price return that is down 20.5%, Endeavour Mining’s 1 year total shareholder return of 65.5%...

In early June 2026, Amneal Pharmaceuticals reported positive interim Phase 4 ELEVATE-PD results for CREXONT in Parkinson’s disease and also received FDA approval, with 180 days of Competitive Generic Therapy exclusivity, for its romidepsin injection solution for cutaneous T-cell lymphoma. The CREXONT data highlighted meaningful gains in “Good On” time and motor control across prior treatment groups, while the romidepsin approval brought an oncology medicine back to the U.S. market in a...

Establishment Labs Holdings (ESTA) has drawn fresh attention after recent share price moves, with the stock up about 11% over the past month and roughly 25% in the past 3 months. See our latest analysis for Establishment Labs Holdings. The recent 7 day share price return of 9.74% and 90 day share price return of 24.95% come on top of a 1 year total shareholder return of 106.18%, pointing to momentum that has been building rather than fading. If you are comparing ESTA with other faster growing...

In recent days, Google Cloud announced a collaboration with Randstad Digital to deploy the Forze Mirate agentic AI solution for Forze Hydrogen Racing, using Gemini Enterprise models to accelerate onboarding and improve knowledge transfer in a high-turnover engineering setting. This project highlights how Randstad is applying advanced AI to complex technical environments, potentially reinforcing its positioning in higher-value digital and engineering talent services. Next, we will examine how...

Recently, Zacks upgraded Brink's to a Rank #2 (Buy), citing a positive shift in analyst earnings estimates and a stronger earnings outlook for the company. This ratings change highlights how revisions to profit expectations can shape investor perception of Brink's evolving cash-management and digital services business model. Next, we'll examine how this more optimistic earnings outlook might influence Brink's broader investment narrative built around AMS and digital solutions. The future of...

Earlier this week, Vornado Realty Trust reported that PENN 2 in New York’s PENN DISTRICT is now 90% leased after signing 10–12 year full-floor agreements with technology tenants Veeva and Altana AI, which is establishing its new headquarters there. This leasing progress at a flagship redevelopment, coupled with increased interest across office REITs, highlights how high-quality, amenity-rich assets may be attracting tenants even as the broader office sector adjusts to new working...

On June 8, 2026, PTC Therapeutics announced that board member Alethia Young resigned to focus on other work commitments, while simultaneously entering a consulting agreement that keeps her advising the company through June 8, 2027. This move comes as PTC Therapeutics reports record revenue driven by strong global uptake of SEPHIENCE, underscoring the company’s emphasis on continuity of commercial and advisory expertise. We’ll now examine how record SEPHIENCE-driven revenue, alongside Alethia...

In May 2026, Maximus, Inc. entered into a second amendment to its Amended and Restated Credit Agreement, securing an additional US$325,000,000 in Tranche B-1 term loans with terms matching its existing term B facilities. The new borrowing, earmarked for revolver repayment, share repurchases, working capital, and related fees, highlights Maximus’ active use of leverage to fund capital returns while maintaining liquidity. We’ll now examine how Maximus’ expanded term loan capacity and planned...

CG Oncology (CGON) is back in focus as investors look ahead to key data from its Phase 3 PIVOT-006 trial and a planned regulatory filing for bladder cancer therapy cretostimogene later this year. See our latest analysis for CG Oncology. Recent excitement around cretostimogene and upcoming conference appearances has not prevented some volatility, with the share price down 20.77% over the past month and 12.78% over 90 days, yet still posting a 31.42% year to date share price return and a very...

Rising tensions between the US and Iran, self defense strikes, and related crude supply disruptions have pushed oil prices higher, putting Diamondback Energy (FANG) firmly back on investors’ radar as a key US shale producer. See our latest analysis for Diamondback Energy. Short term, the stock has been choppy, with the share price falling 6.67% over the past week even as it gained 11.04% over 90 days and delivered a 35.39% total shareholder return over the past year. This pattern suggests...

Tarsus Pharmaceuticals recently presented at the 46th Annual William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York, highlighting its eye-care portfolio and commercial progress. These conferences gave the company a high-visibility forum to emphasize growing real-world adoption of XDEMVY, supported by intensive direct-to-consumer marketing efforts. We’ll now examine how accelerating XDEMVY awareness and uptake, spotlighted at these...

In recent days, Clear Street analyst Tim Moore highlighted Willdan Group’s potential upside, citing expected revenue and adjusted EBITDA growth from power grid modernization and rising demand for energy-efficient and AI datacenter solutions, while company insiders sold about US$6.1 million of stock over the past three months. This combination of bullish analyst commentary on AI datacenter exposure and concurrent insider selling offers a contrasting signal about management’s and the market’s...

Art Group Holdings (SEHK:565) has called an extraordinary general meeting for July 2026 to seek shareholder approval to renew its mandate to issue up to 20% new shares. See our latest analysis for Art Group Holdings. At a share price of HK$3.06, Art Group Holdings has seen strong momentum build recently, with a 30 day share price return of 4.79% and a year to date share price return of 120.14%. The 1 year total shareholder return of 197.09% and very large 3 year total shareholder return...

Earnings and Analyst Sentiment Put Kingboard Laminates Holdings (SEHK:1888) in Focus Kingboard Laminates Holdings (SEHK:1888) is back on investors’ radar after its latest earnings report showed improved quarterly revenue and net profit versus a year earlier, alongside continued supportive views from major banks. See our latest analysis for Kingboard Laminates Holdings. The latest move has come on top of rapid momentum, with the share price up 9.8% in the last session and a 30 day share price...

With the Bank of Canada expected to maintain its current interest rate stance amid contained inflation and sluggish growth, Canadian investors are navigating a landscape where economic fundamentals are playing a crucial role in shaping market dynamics. In this context, penny stocks—though an outdated term—continue to draw interest for their potential value and growth opportunities. By identifying those with strong financials and promising trajectories, investors can uncover hidden gems within...

Recent performance snapshot UniCredit (BIT:UCG) has drawn investor attention after recent price moves, with the stock roughly flat over the past month and higher over the past 3 months, against a backdrop of mixed short term returns. See our latest analysis for UniCredit. At a share price of €70.41, UniCredit’s recent pullback over the past week contrasts with its positive 3 month share price return and very large 5 year total shareholder return. This suggests long term momentum remains...

On 3 June 2026, Bristol Myers Squibb announced a clinical trial collaboration and supply agreement under which Arcus Biosciences will provide its investigational HIF-2a inhibitor casdatifan for new combination arms in the Phase 1/2 ROSETTA RCC-208 study in advanced renal cell carcinoma, while both parties retain rights to their respective assets in this non-exclusive deal. This collaboration highlights growing external interest in casdatifan as a potential component of combination regimens,...